靶向PI3K-β和-δ克服弥漫大B细胞淋巴瘤的BTK耐药
研究建立3株同基因型伊布替尼耐药DLBCL细胞系,发现BTK水平降低而PI3K/AKT信号增强,PI3K-β上调驱动耐药;PI3K-β/δ双抑制剂KA2237可逆转耐药并协同化疗抑制生长。
要点
- 伊布替尼耐药DLBCL细胞中BTK降低、PI3K/AKT信号增强。
- PI3K-β上调驱动耐药,阻断PI3K-β/δ可逆转耐药。
- KA2237与化疗药联用协同抑制耐药细胞代谢生长。
核心结论
- 伊布替尼耐药DLBCL细胞中PI3K/AKT轴代偿性上调,靶向PI3K-β/δ可克服耐药。
研究设计与样本
- 研究建立3株同基因型伊布替尼耐药DLBCL细胞系,探究耐药相关失调通路。
主要发现
- 耐药细胞以BTK水平降低和PI3K/AKT信号增强为标志。
- PI3K-β表达上调驱动伊布替尼耐药,阻断PI3K-β/δ活性可逆转耐药。
- KA2237降低耐药细胞致瘤特性及PI3K/AKT/mTOR生存信号。
- KA2237与现有化疗药联用协同抑制代谢生长。
临床怎么用
- 对伊布替尼耐药的ABC型DLBCL,可考虑靶向PI3K-β/δ联合化疗的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma; 40% of patients relapse after a complete response or are refractory to therapy. To survive, the activated B-cell (ABC) subtype of DLBCL relies upon B-cell receptor signaling, which can be modulated by the activity of Bruton tyrosine kinase (BTK). Targeting BTK with ibrutinib, an inhibitor, provides a therapeutic approach for this subtype of DLBCL. However, non-Hodgkin lymphoma is often resistant to ibrutinib or acquires resistance soon after exposure. We explored how this resistance develops. We generated 3 isogenic ibrutinib-resistant DLBCL cell lines and investigated the deregulated pathways known to be associated with tumorigenic properties. Reduced levels of BTK and enhanced phosphatidylinositol 3-kinase (PI3K)/AKT signaling were hallmarks of these ibrutinib-resistant cells. Upregulation of PI3K-β expression was demonstrated to drive resistance in ibrutinib-resistant cells, and resistance was reversed by the blocking activity of PI3K-β/δ. Treatment with the selective PI3K-β/δ dual inhibitor KA2237 reduced both tumorigenic properties and survival-based PI3K/AKT/mTOR signaling of these ibrutinib-resistant cells. In addition, combining KA2237 with currently available chemotherapeutic agents synergistically inhibited metabolic growth. This study elucidates the compensatory upregulated PI3K/AKT axis that emerges in ibrutinib-resistant cells.
引用
- Jain N, Singh S, Laliotis G, et al. Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32926124. doi:10.1182/bloodadvances.2020001685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。